EQ 8
Alternative Names: EQ-8Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Johns Hopkins University
- Developer AxoProtego Therapeutics; Johns Hopkins University
- Class Antiparkinsonians; Neuroprotectants; Quinolines; Small molecules
- Mechanism of Action HSP90 heat-shock protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis; Parkinson's disease
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Multiple-sclerosis in USA
- 28 Sep 2024 No recent reports of development identified for research development in Parkinson's-disease in USA
- 06 Aug 2020 Early research in Multiple sclerosis in USA (unspecified route)